Raluca Verona

6.2k total citations · 2 hit papers
61 papers, 3.2k citations indexed

About

Raluca Verona is a scholar working on Oncology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Raluca Verona has authored 61 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 32 papers in Hematology and 27 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Raluca Verona's work include Multiple Myeloma Research and Treatments (32 papers), Monoclonal and Polyclonal Antibodies Research (27 papers) and CAR-T cell therapy research (26 papers). Raluca Verona is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Monoclonal and Polyclonal Antibodies Research (27 papers) and CAR-T cell therapy research (26 papers). Raluca Verona collaborates with scholars based in United States, Netherlands and Spain. Raluca Verona's co-authors include Marisa S. Bartolomei, Mellissa R.W. Mann, Jacqueline A. Lees, Leisha D. Nolen, Jeffrey M. Trimarchi, Richard M. Schultz, Kenneth H. Moberg, Adam S. Doherty, Niels W.C.J. van de Donk and Catherine Rogers and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Raluca Verona

59 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

2022 350 citations Ajai Chari, Monique C. Minnema et al. profile →
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Peers

Countries citing papers authored by Raluca Verona

Since Specialization

Citations

This map shows the geographic impact of Raluca Verona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raluca Verona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raluca Verona more than expected).

Fields of papers citing papers by Raluca Verona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raluca Verona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raluca Verona. The network helps show where Raluca Verona may publish in the future.

Co-authorship network of co-authors of Raluca Verona

This figure shows the co-authorship network connecting the top 25 collaborators of Raluca Verona. A scholar is included among the top collaborators of Raluca Verona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raluca Verona. Raluca Verona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma	Clinical Cancer Research	Christie P.M. Verkleij, Marloes E.C. Broekmans et al.	25
2	GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review breakdown →	Blood Cancer Journal	Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al.	51
3	Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study	Cancer	Ajay K. Nooka, Cesar Rodriguez et al.	36
4	Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma	Cancer	Thomas G Martin, María‐Victoria Mateos et al.	28
5	POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)	Clinical Lymphoma Myeloma & Leukemia	Niels W.C.J. van de Donk, Philippe Moreau et al.	3
6	MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study	Clinical Lymphoma Myeloma & Leukemia	Salomon Manier, Ajay K. Nooka et al.	0
7	Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma	Blood Advances	Suzette Girgis, Shun Xin Wang Lin et al.	30
8	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas	Cancer Research Communications	Anne W. J. Martens, Renate de Boer et al.	9
9	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma	Blood Advances	Christie P.M. Verkleij, Marloes E.C. Broekmans et al.	117
10	Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma	Blood	Amrita Krishnan, Monique C. Minnema et al.	40
11	Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma	Blood	Christie P.M. Verkleij, Marloes E.C. Broekmans et al.	7
12	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy	Lung Cancer	Jeffrey C. Thompson, Wei‐Ting Hwang et al.	93
13	Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity	Cancer Immunology Research	Karla R. Wiehagen, Natasha Girgis et al.	135
14	TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1	The Journal of Immunology	Olesya Chornoguz, Karen Leander et al.	30
15	Maintenance of Paternal Methylation and Repression of the Imprinted H19 Gene Requires MBD3	PLoS Genetics	Kimberly J. Reese, Shu Lin et al.	65
16	X-tra! X-tra! News from the Mouse X Chromosome	Developmental Biology	Joanne L. Thorvaldsen, Raluca Verona et al.	35
17	Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics	Genes & Development	Aaron Aslanian, Phillip J. Iaquinta et al.	145
18	Role of H19 3′ sequences in controlling H19 and Igf2 imprinting and expression	Genomics	Raluca Verona, Marisa S. Bartolomei	11
19	Disruption of Imprinted Gene Methylation and Expression in Cloned Preimplantation Stage Mouse Embryos1	Biology of Reproduction	Mellissa R.W. Mann, Young Gie Chung et al.	259
20	E2F Activity Is Regulated by Cell Cycle-Dependent Changes in Subcellular Localization	Molecular and Cellular Biology	Raluca Verona, Kenneth H. Moberg et al.	192

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact